AAL

Drug Stock Reaches New Highs on Growth-Hormone Win

ASND stock is pacing for its best day ever

Digital Content Manager
Mar 4, 2019 at 9:52 AM
facebook X logo linkedin


The shares of Ascendis Pharma (NASDAQ:ASND) are up 66% at $114.96 this morning, after the company's pediatric growth-hormone drug, TransCon, succeeded in meeting the main goal of a late-stage trial. The win has ASND trading at record highs, and pacing for its best day ever.

Prior to today's rally, the stock was up 10.6% year-to-date, and was struggling to surmount the $75-$77 area -- home to its previous all-time highs. Now, ASND is traveling well above its old highs, peaking at $115.50 in early trading. 

Analysts have shown resounding optimism for Ascendis of late, with all eight giving it a "strong buy" rating. However, there could be some price-target hikes in the cards, as the consensus 12-month target price of $85.78 now represents a steep discount to the stock's current perch. 

Meanwhile, plenty of short sellers could be kicking rocks today. Short interest rose 27.3% in the most recent reporting period. At ASND's average daily trading volume, it would take almost a week for bears to cover these pessimistic positions -- hinting at potential tailwinds in the form of a short squeeze. 

 

Same-Day Trading Power: +227% YTD and Counting  — Get in for $10!

We're celebrating 44 years of helping traders win, and you can now tap into one of our most explosive services — Dynamite Day Trading Signals — for just $10.

This service was built for one thing: capturing intraday gains with precision. 

Access two highly-vetted options trades each week -  Complete with defined entries, exits, and a clear plan for same-day profits.

👉 Click Here to Learn More and Position Yourself to Take Action When the Next Alert Hits.